Publications

5891 Results

Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer

Authors
B Felsheim;A Fernandez Martinez;C Fan;A Pfefferle;M Hayward;K Hoadley;G Somlo;L Carey;W Sikov;C Perou
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/C40603

Association of Baseline Global Inflammation Score with Clinical Outcomes: Secondary Analysis from Alliance A011502

Authors
S Gandhi;K Ballman;S Reed;M Holmes;K Visvanathan;B Symington;M Carvan;C Matyka;A Weiss;E Winer;W Razaq;L Carey;A Partridge;W Chen
Journal / Conference
San Antonio Breast Cancer Symposium (December 10-13, 2024, San Antonio, TX), poster
Year
2024
Research Committee(s)
Breast
Study Number(s)
CTSU/A011502

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;T Al Baghdadi;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Lymphoma
Study Number(s)
S2207

Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Authors
V Liu;M Othus;R Ries;J Neru;E Pogosova-Agadjanyan;F Appelbaum;L Beppu;T Chauncey;H Erba;J Godwin;M Fitzgibbon;M Fang;A Moseley;J Radich;C Willman;F Wu;S Meshinchi;D Stirewalt
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

Representation of Minorities in Therapeutic Clinical Trials – A 15-Year Review of Lymphoma Cooperative Group Studies

Authors
A Alencar;E Paskett;S Geyer;L Pederson;T Dokter;N Ghosh;K Adekola;J Unger;O Jegede;J Friedberg;B Kahl;S Dinner;N Bartlett;K Blum;J Leonard
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Cancer Care Delivery and Lymphoma

Consent to Future Use of Residual and Banked Specimens among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Authors
D Olivieri;A Berridge-Green;M Othus;J Radich;A Advani;H Erba;R Walter
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia

The Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Adult Patients with B-cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Trial

Authors
D DeAngelo;V Yin;A Advani;S Lugar;J Fulcher;M Liedtke;G Uy;S Dinner;L Wilde;H Erba;M Litzow;R Stone;P Mohindra;J Bogart;W Stock
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), oral
Year
2024
Research Committee(s)
Leukemia

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Authors
J Altman;Sun;Perl;Little;Gore;L Michaelis;G Uy;Y Abaza;Abedin;Reagan;Atallah;Luger;M Litzow
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Authors
S Ailawadhi;A Hoering;JC Ye;B Lipe;D Calverley;T Chauncey;K Gowin;S Holstein;E Campagnaro;V Rajkumar;S Usmani;A Rosenthal;J Aiello;R Orlowski
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Myeloma
Study Number(s)
S2209

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Authors
N Podoltsev;Z Sun;M Litzow;E Paietta;K Roberts;Y Xhang;J Racevckis;H Lazarus;J Rowe;D Arber;M Wieduwilt;M Liedtke;J Bergeron;B Wood;Y Zhao;G Wu;T Chang;W Zhang;K Pratz;S Dinner;N Frey;S Gore;B Bhatnagar;E Atallah;G Uy;D Jeyakumar;T Lin;C Willman;D De Angelo;S Patel;M Elliott;A Advani;D Tzachanis;P Vachhani;R Bhave;E Sharon;R Little;H Erba;R Stone;C Mullighan;M Tallman;S Luger;R Mattison
Journal / Conference
ASH Annual Meeting (December 7-10, 2024, in San Diego, CA), poster
Year
2024
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1910